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INTRODUCTION
Idiopathic sudden sensorineural hearing loss (SSNHL) is com-
monly associated with tinnitus and ear fullness, and is often ac-
companied by vertigo. Although some patients recover sponta-
neously without treatment, therapeutic intervention that includes 
systemic steroid therapy and intra-tympanic steroid injections is 
typically used to promote prompt recovery of hearing (1-4). Ther-
apeutic efficacy in patients with SSNHL depends on the treat-
ment regimen and a variety of prognostic factors including age, 
treatment delay, diabetes mellitus, hypertension, and audiologi-
cal patterns (5-7).
  Vertigo accompanies SSNHL in 30% to 40% cases, and is of-
ten considered a poor prognostic factor (2). However, not all stud-
ies have confirmed that vertigo is an unfavorable prognostic sign 
(5). The reason for these inconsistent findings is that vertigo is not 
a specific disease entity but rather a symptom caused by many 
different etiologies. The most common diseases associated with 
vertigo in SSNHL include benign paroxysmal positional vertigo 
(BPPV), vestibular neuropathy, central vertigo, and non-specific 
dizziness. Although there have been some attempts to describe 
the relationships between the results of caloric tests and progno-
ses (6, 8-10), studies investigating hearing outcome in SSNHL 
with BPPV are rare.
  The purpose of this study is to determine the role of BPPV as 
a prognostic factor in patients with SSNHL by controlling for 
confounding factors such as initiation of treatment, age, other 
vestibular abnormality and diabetes. 
Objectives. The prognostic significance of vertigo in patients with idiopathic sudden sensorineural hearing loss (SSNHL) re-
mains a matter of debate because vertigo is associated with many different vestibular disorders. The purpose of this 
study is to determine the role of benign paroxysmal positional vertigo (BPPV) as a prognostic factor in patients with 
SSNHL.
Methods. We conducted a retrospective study of 298 patients with SSNHL. Hearing outcomes were evaluated by assess-
ments of pre-treatment hearing and hearing gain. Comparative multivariate analyses between prognostic factors and 
hearing outcome were conducted. 
Results. Thirty-eight (12.7%) SSNHL patients were found to also have BPPV. BPPV showed significant negative prognostic 
factors in hearing outcome on multivariate analysis (odds ratio, 0.15). In comparison to average pure tone audiome-
try (PTA), patients diagnosed with SSNHL with BPPV exhibited poorer hearing in pre- and post-treatment PTA 
compared to SSNHL without BPPV. Old age (>60 years), pre-treatment hearing, and canal paresis were significant 
outcome predictors. 
Conclusion. BPPV in SSNHL patients, representing definitive vestibular damage, was closely related to poor prognosis.
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MATERIALS AND METHODS
We reviewed the medical records of 298 patients with SSNHL 
treated in the Department of Otorhinolaryngology-Head and 
Neck Surgery, Kangbuk Samsung Hospital, Seoul, Korea between 
January 2004 and January 2009. All patients experienced idio-
pathic unilateral sensorineural hearing loss (SNHL) that devel-
oped within 72 hours and was not associated with other known 
pathologies, including Meniere’s disease, autoimmune disease, 
ototoxicity, or neoplasm. The patients all had minimum 25 dB 
hearing loss at three consecutive frequencies. All patients received 
steroid treatment (injection of methylprednisolone 1 mg/kg for 
five days then tapered over five days) started concomitantly with 
low molecular weight dextran. Patients were excluded from the 
study if they had an interval of ten or more days before initial 
treatment, if central vertigo was suspected from brain MRI or if 
they had diabetes that was intolerable of systemic steroid treat-
ment. 
  Vestibular function test (VFT) was performed by using video-
nystagmography (VNG) to assess the presence of BPPV and to 
evaluate canal function. VFT findings were divided into three 
categories: BPPV; canal paresis (CP); and non-specific findings 
that include headshaking nystagmus without CP, directional pre-
ponderance without CP or non-specific nystagmus. Pure tone 
audiometry (PTA) was performed on the first day of admission, 
then every other day after the initiation of treatment and every 
three weeks after steroid treatments were completed. Subjects 
with <three months of follow-up were excluded from this study 
because of uncertain hearing outcome. 
  The Siegel classification (11) was used to evaluate the outcome 
of patients on the last visit, using average gain in dB in four au-
diometric speech frequencies of 500 Hz, 1,000 Hz, 2,000 Hz, 
and 4,000 Hz. The classification is as follows: no improvement, 
less than 15 dB of gain; slight improvement, more than 15 dB of 
gain and a final hearing loss poorer than 45 dB; moderate im-
provement, more than 15 dB of gain and final hearing level be-
tween 25 and 45 dB; and complete improvement, hearing level 
better than 25 dB regardless of the size of the gain. Multivariate 
analyses between possible prognostic factors, including BPPV 
and hearing outcome, was conducted. The pre and post-treatment 
hearing were also compared between SSNHL with BPPV and 
without BPPV. We obtained Kangbuk Samsung Hospital Institu-
tional Review Board approval for this study.
Statistical analysis
Statistical analyses were performed using PASW Statistics ver. 
17.0 (SPSS Inc., Chicago, IL, USA). Pearson’s chi-square analy-
ses were performed to identify statistically significant differences 
between the prognostic factors and hearing outcome. Multivari-
ate logistic regression analysis was further performed according 
to the prognostic factors. For multivariate analysis, we divided 
hearing results into two categories: the first (good recovery) with 
moderate to complete improvement and the second (poor re-
covery) with no to slight improvement. The Mann-Whitney test 
was performed for average PTA.
RESULTS
The mean interval between pre- and post-treatment PTA was 4.6 
months with a range from 3 to 10 months. Mean age in SSNHL 
was 48.0±16.1 months. SSNHL with BPPV showed worse pre-
treatment hearing results than SSNHL without BPPV (P=0.01), 
(Fig. 1). Only with this result, it was hard to conclude that BPPV 
itself have a negative prognostic sifnificance. We analyse prog-
nostic significance of BPPV with multivariated analysis consid-
ering other factor that affect post-treatment hearing reulsts. 
  Overall hearing outcome showed complete improvement in 
112 patients (37.5%), moderate improvement in 33 patients 
(11.1%), slight improvement in 33 patients (11.1%), and no im-
provement in 120 patients (40.2%). Thirty-eight patients (12.7%) 
were diagnosed with BPPV in SSNHL. Table 1 summarizes the 
hearing results by Siegel classification among SSNHL patients 
according to the presence of BPPV. In SSNHL with BPPV, 68.4% 
(26/38) of patients showed profound hearing loss (>90 dB HL 
of pre-treatment PTA). All patient characteristics are given in Ta-
Table 1. Hearing outcome in SSNHL according to the presence of 
BPPV
Complete 
improve-
ment
Moderate 
improve-
ment
Slight
improve-
ment
No im-
prove-
ment
Total
SSNHL 109 
(41.9)
33  
(12.6)
21  
(8.0)
97  
(37.3)
260
SSNHL with BPPV  3 (7.8) 0 (0) 12 (31.5) 23 (60.5)   38
Values are presented as number (%).
SSNHL: idiopathic sudden sensorineural hearing loss; BPPV: benign 
paroxysmal positional vertigo.
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Fig. 1. The average pure tone audiometry (PTA) between pre- and 
post-treatment in idiopathic sudden sensorineural hearing loss 
(SSNHL) patients with benign paroxysmal positional vertigo (BPPV) 
and SSNHL patients without BPPV.  Lee NH et al.: Idiopathic Sudden Sensory Hearing Loss with BPPV    201
ble 2. BPPV, age, CP, and pre-treatment hearing are significantly 
associated with hearing outcome. However, there were no dif-
ferences in hearing outcome according to sex or non-specific 
VFT findings (Table 2). Only 7.9% of patients showed good re-
covery in SSNHL with BPPV while 54.6% of patients showed 
good recovery in SSNHL without BPPV. 
  After excluding the non-significant factors, multivariate analy-
sis of potential prognostic factors demonstrated that BPPV, age, 
CP, and pre-treatment PTA levels were associated with hearing 
outcome (Table 3). BPPV, canal paresis and age older than 60 
had a worse outcome with adjusted odds ratios (aOR) of 0.43, 
0.04, 0.15, respectively. On the other hand, pre-treatment PTA 
levels ≤90 were significantly correlated with better hearing out-
come (aOR=3.38).
DISCUSSION
Many studies have reported prognostic factors associated with 
SSNHL. The most frequently noted prognostic factors include 
age, pre-treatment hearing, time to treatment initiation, vertigo, 
canal paresis and associated systemic disease (8-10). The pres-
ence of vertigo is usually considered a poor prognostic factor, 
but the relationship between vertigo and hearing outcome con-
tinues to be debated (11, 12). First, vertigo is not a distinct dis-
ease but rather a symptom with several possible etiologies. Ver-
tigo is a common manifestation of a variety of vestibular insults. 
Second, many previous reports did not account for other prog-
nostic factors that may affect hearing results such as initial hear-
ing status, age, presence of systemic disease, and treatment on-
set. These factors may interfere with analyzing the role of verti-
go in patient prognosis. 
  Many reports have shown that the presence of diabetes and 
late initiation of treatment from the onset of hearing loss are as-
sociated with reduced responsiveness to steroid treatment (6, 13). 
For this reason, in order to analyze the prognostic significance 
of BPPV itself, we controlled possible prognostic factors by only 
including patients who were <10 days from treatment initiation 
and excluding patients with diabetes. 
  Abnormal VFT findings in patients with vertigo in our study 
are composed of BPPV, CP, non-specific findings such as direc-
tional prepoderance (DP) without CP, headshaking nystagmus 
without CP, and other non-specific causes of nystagmus. Among 
these, VFT findings with prognosis are CP and BPPV. In SSNHL 
with BPPV, only three of the 38 patients (7.8%) achieved a com-
plete improvement. These findings are inconsistent with those in 
patients with vertigo in previous reports. Moskowitz et al. (2) 
and Mamak et al. (14) reported rates of 14% and 23.1%, re-
spectively, for complete recovery in SSNHL patients with verti-
go. Non-specific dizziness, which does not affect prognosis un-
like BPPV and CP, might be diagnosed in patients with vertigo. 
We did not add data in this study about involved canal in BPPV 
patients. Hearing outcome was not different according to the 
subtype of BPPV. We thought that the presence of BPPV itself 
reflect serious labyrinthine damage no matter what canals were 
involved. 
  The most commonly accepted cause of cochlear damage in 
SSNHL is viral infection, while hypoperfusion is the etiology in 
other cases (15). Although most diagnoses are idiopathic for 
BPPV, labyrinth viral infections are implicated by some reports 
(16), and Schuhknecht (17) postulated that otoliths may dislodge 
from infracted utricular macula and accumulate in the semicir-
cular canal. Therefore, SSNHL can be associated with the occur-
rence of secondary BPPV. Some reports have shown that vertigo 
is present more frequently in patients with profound hearing loss 
Table 2. Baseline characteristics of patients with SSNHL 
Potential prognostic 
factors
All  
patients 
(n=298)
Good  
recovery 
(n=145)
Poor  
recovery 
(n=153)
P-value
BPPV 
   Presence
   Absence
38
260
3 (7.9)
142 (54.6)
35 (92.1)
118 (45.4)
0.00*
Sex 
   Male
   Female
151
147
74 (49.0)
71 (48.3)
77 (51.0)
76 (51.7)
0.90
Age
   ≤60 years 
   >60 years  
214
84
113 (52.8)
32 (38.1)
101 (47.2)
52 (61.9)
0.02*
Canal paresis
   Presence  
   Absence  
48
250
2 (4.2)
143 (57.2)
46 (95.8)
107 (42.8)
0.00*
Non-specific  
  finding in VFT
   Presence  
   Absence  
28
270
13 (46.4)
132 (48.9)
15 (53.6)
138 (51.1)
0.80
Pre-treatment PTA   
  level
   ≤90 
   >90  
226
72
132 (58.4)
13 (18.1)
94 (41.6)
59 (81.9)
0.00*
*Statistically significant.
SSNHL: idiopathic sudden sensorineural hearing loss; BPPV: benign 
paroxysmal positional vertigo, VFT: vestibular function test; PTA: pure 
tone audiometry.
Table 3. Multivariate analysis of prognostic factors in patients with 
SSNHL 
Prognostic factors Adjusted odds ratio 
(95% confidence interval) P-value
Age (>60 vs. ≤60) 0.43 (0.24-0.78)  0.005
Canal paresis 
  (presence vs. absence)
0.04 (0.01-0.20) 0.000
BPPV 
  (presence vs. absence)
0.15 (0.04-0.58) 0.006
Pre-treatment PTA levels 
  (≤90 vs. >90 dB HL)
3.38 (1.59-7.18) 0.002
SSNHL: idiopathic sudden sensorineural hearing loss; BPPV: benign 
paroxysmal positional vertigo; PTA: pure tone audiometry.202    Clinical and Experimental Otorhinolaryngology   Vol. 3, No. 4: 199-202, December 2010
(18). The presence of profound hearing loss implies that cochlear 
damage is probably too extensive for therapy to have a benefi-
cial effect. BPPV may represent severe labyrinth damage that 
may result in poorer hearing recovery. In our study, many pa-
tients with BPPV (68.4%) exhibited profound hearing loss and 
poor hearing recovery. 
  Our results showing that age, pre-treatment hearing and CP 
are associated with prognosis are consistent with other studies 
(6, 8-10, 19, 20). Although a consensus regarding the prognostic 
importance of age does not exist (14), most authors suggest that 
profound hearing loss has a worse prognosis in SSNHL. Khetar-
pal (21) studied temporal bone histology in patients with sud-
den deafness and vertigo and suggested that vertigo may be 
caused by biochemical alterations in the inner ear. Simmons (22) 
hypothesized that vertigo with SSNHL may be the result of a 
membrane break near the vestibule. Therefore, canal dysfunc-
tion may be another indicator of the extent and the severity of 
inner ear injury. 
  In conclusion, this is the study to statistically evaluate the prog-
nostic significance of BPPV in patients with SSNHL adjusting 
other prognostic factors. SSNHL with BPPV patients were ex-
pected to showed poor initial hearing level and BPPV itself have 
a negative prognostic significance that represent labyrinthine 
damage. 
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